Abstract
Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.
| Original language | English |
|---|---|
| Pages (from-to) | 781-787 |
| Number of pages | 7 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 5 |
| Issue number | 1 |
| Publication status | Published - 2009 |
Keywords
- First-line setting
- Non-small cell lung cancer
- Non-squamous carcinoma
- Pemetrexed
ASJC Scopus subject areas
- Pharmacology (medical)
- Medicine(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
- Safety Research
- Chemical Health and Safety
Fingerprint Dive into the research topics of 'Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer'. Together they form a unique fingerprint.
Cite this
Ricciardi, S., Tomao, S., & De Marinis, F. (2009). Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Therapeutics and Clinical Risk Management, 5(1), 781-787.